Relief_NN
of_IN
cyclin_NN
A_NN
gene_NN
transcriptional_JJ
inhibition_NN
during_IN
activation_NN
of_IN
human_JJ
primary_JJ
T_NN
lymphocytes_NNS
via_IN
CD2_NN
and_CC
CD28_NN
adhesion_NN
molecules_NNS
._.

Cyclin_NN
A_NN
transcription_NN
is_VBZ
cell_NN
cycle_NN
regulated_VBN
and_CC
induced_VBN
by_IN
cell_NN
proliferative_JJ
signals_NNS
._.

To_TO
understand_VB
the_DT
mechanisms_NNS
underlined_VBN
in_IN
this_DT
regulation_NN
in_IN
normal_JJ
human_JJ
cells_NNS
,_,
we_PRP
have_VBP
analyzed_VBN
in_FW
vivo_FW
protein-DNA_JJ
interactions_NNS
at_IN
the_DT
Cyclin_NN
A_NN
locus_NN
in_IN
primary_JJ
T_NN
lymphocytes_NNS
._.

Stimulation_NN
of_IN
purified_VBN
T_NN
lymphocytes_NNS
by_IN
a_DT
combination_NN
of_IN
monoclonal_JJ
antibodies_NNS
directed_VBN
at_IN
CD2_NN
and_CC
CD28_NN
adhesion_NN
molecules_NNS
gives_VBZ
rise_NN
to_TO
a_DT
long_RB
lasting_JJ
proliferation_NN
in_IN
the_DT
absence_NN
of_IN
accessory_JJ
cells_NNS
._.

Cyclin_NN
A_NN
was_VBD
observed_VBN
after_IN
4_CD
days_NNS
of_IN
costimulation_NN
with_IN
anti_JJ
CD2_NN
+_CC
CD28_NN
whereas_IN
stimulation_NN
by_IN
anti_JJ
CD2_NN
or_CC
anti_JJ
CD28_NN
alone_RB
was_VBD
not_RB
effective_JJ
._.

In_FW
vivo_FW
genomic_JJ
DMS_NN
footprinting_NN
revealed_VBD
upstream_JJ
of_IN
the_DT
major_JJ
transcription_NN
initiation_NN
sites_NNS
,_,
the_DT
presence_NN
of_IN
at_IN
least_JJS
three_CD
protein_NN
binding_NN
sites_NNS
,_,
two_CD
of_IN
which_WDT
were_VBD
constitutively_RB
occupied_VBN
._.

They_PRP
bind_VBP
in_FW
vitro_FW
respectively_RB
ATF-1_NN
and_CC
NF-Y_NN
proteins_NNS
._.

The_DT
third_JJ
site_NN
was_VBD
occupied_VBN
in_IN
quiescent_JJ
cells_NNS
or_CC
in_IN
cells_NNS
stimulated_VBN
by_IN
anti_JJ
CD2_NN
or_CC
anti_JJ
CD28_NN
alone_RB
._.

The_DT
mitogenic_JJ
combination_NN
of_IN
anti_JJ
CD2_NN
+_CC
anti_JJ
CD28_NN
released_VBD
the_DT
footprint_NN
as_IN
cells_NNS
were_VBD
committed_VBN
to_TO
proliferation_NN
._.

Consistent_JJ
with_IN
theses_DT
results_NNS
,_,
nuclear_JJ
extracts_NNS
prepared_VBN
from_IN
quiescent_JJ
cells_NNS
formed_VBD
a_DT
specific_JJ
complex_NN
with_IN
this_DT
element_NN
,_,
whereas_IN
extracts_NNS
prepared_VBN
from_IN
cells_NNS
treated_VBN
with_IN
anti_JJ
CD2_NN
+_CC
anti_JJ
CD28_NN
failed_VBD
to_TO
do_VB
so_RB
after_IN
cells_NNS
entered_VBD
a_DT
proliferative_JJ
state_NN
._.

